Kayne Anderson Rudnick Investment Management
AKRO

Kayne Anderson Rudnick Investment Management’s Akero Therapeutics AKRO Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-89
Closed -$1K – 601
2022
Q1 		$1K Buy
+89
New +$1.56K ﹤0.01% 614

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's AKRO Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Akero Therapeutics (AKRO) in Q2 2022, closing a stake of 89 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in AKRO in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 113 funds tracked by Wall St. Rank hold AKRO as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Akero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 89 Akero Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Akero Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Akero Therapeutics position peaked at $1K in Q1 2022.
  • 113 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.